A
Anna Santacruz
Researcher at Washington University in St. Louis
Publications - 16
Citations - 4528
Anna Santacruz is an academic researcher from Washington University in St. Louis. The author has contributed to research in topics: Gantenerumab & Solanezumab. The author has an hindex of 10, co-authored 15 publications receiving 3488 citations.
Papers
More filters
Journal ArticleDOI
Clinical and Biomarker Changes in Dominantly Inherited Alzheimer’s Disease
Randall J. Bateman,Chengjie Xiong,Tammie L.S. Benzinger,Anne M. Fagan,Alison Goate,Nick C. Fox,Daniel S. Marcus,Nigel J. Cairns,Xianyun Xie,Tyler Blazey,David M. Holtzman,Anna Santacruz,Virginia Buckles,Angela Oliver,Krista L. Moulder,Paul S. Aisen,Bernardino Ghetti,William E. Klunk,Eric McDade,Ralph N. Martins,Colin L. Masters,Richard Mayeux,John M. Ringman,Martin N. Rossor,Peter R. Schofield,Reisa A. Sperling,Stephen Salloway,John C. Morris +27 more
TL;DR: In this paper, a longitudinal study of 128 patients with Alzheimer's disease was conducted, where the authors used the participant's age at baseline assessment and the parent's age to calculate the estimated years from expected symptom onset (age of the participant minus parent's ages at symptom onset).
Journal Article
Clinical and biomarker changes in dominantly inherited alzheimer's disease
Peter R. Schofield,Randall J. Bateman,Chengjie Xiong,Tls Benzinger,Anne M. Fagan,Alison Goate,Nick C. Fox,Daniel S. Marcus,Nigel J. Cairns,X Xie,Tyler Blazey,David M. Holtzman,Anna Santacruz,Virginia Buckles,Angela Oliver,Krista L. Moulder,Paul S. Aisen,Bernardino Ghetti,William E. Klunk,Eric McDade,Ralph N. Martins,Colin L. Masters,Richard Mayeux,John M. Ringman,Martin N. Rossor,Reisa A. Sperling,Stephen Salloway,John C. Morris +27 more
TL;DR: It is found that autosomal dominant Alzheimer's disease was associated with a series of pathophysiological changes over decades in CSF biochemical markers of Alzheimer’s disease, brain amyloid deposition, and brain metabolism as well as progressive cognitive impairment.
Journal ArticleDOI
Effects of Age and Amyloid Deposition on Aβ Dynamics in the Human Central Nervous System
Yafei Huang,Rachel Potter,Wendy Sigurdson,Anna Santacruz,Shirley Shih,Yo-El Ju,Tom Kasten,John C. Morris,Mark A. Mintun,Stephen P. Duntley,Randall J. Bateman +10 more
TL;DR: A reduction in the linear increase in the Aβ levels in CSF samples that is associated with amyloid deposition and a decreased CSF Aβ diurnal pattern associated with increasing age disrupt the normal physiology of Aβ dynamics and may contribute to AD.
Journal ArticleDOI
The DIAN-TU Next Generation Alzheimer's prevention trial: Adaptive design and disease progression model.
Randall J. Bateman,Tammie L.S. Benzinger,Scott M. Berry,David B. Clifford,Cynthia Duggan,Anne M. Fagan,Kathleen Fanning,Martin R. Farlow,Jason Hassenstab,Eric McDade,Susan Mills,Katrina L. Paumier,Melanie Quintana,Stephen Salloway,Anna Santacruz,Lon S. Schneider,Guoqiao Wang,Chengjie Xiong +17 more
TL;DR: With completion of enrollment of the first two drug arms, the DIAN‐TU now plans to add new drugs to the platform, designated as the Next Generation (NexGen) prevention trial.
Journal ArticleDOI
A trial of gantenerumab or solanezumab in dominantly inherited Alzheimer's disease.
Stephen Salloway,Martin R. Farlow,Eric McDade,David B. Clifford,Guoqiao Wang,Jorge J. Llibre-Guerra,Janice M. Hitchcock,Susan Mills,Anna Santacruz,Andrew J. Aschenbrenner,Jason Hassenstab,Tammie L.S. Benzinger,Brian A. Gordon,Anne M. Fagan,Kelley Coalier,Carlos Cruchaga,Alison Goate,Richard J. Perrin,Chengjie Xiong,Yan Li,John C. Morris,B. Joy Snider,Catherine J. Mummery,G. Mustafa Surti,Didier Hannequin,David Wallon,Sarah B. Berman,James J. Lah,Ivonne Z. Jimenez-Velazquez,Erik D. Roberson,Christopher H. van Dyck,Lawrence S. Honig,Raquel Sánchez-Valle,William S. Brooks,Serge Gauthier,Douglas Galasko,Colin L. Masters,Jared R. Brosch,Ging-Yuek Robin Hsiung,Suman Jayadev,Maïté Formaglio,Mario Masellis,Roger Clarnette,J. Pariente,Bruno Dubois,Florence Pasquier,Clifford R. Jack,Robert A. Koeppe,Peter J. Snyder,Paul S. Aisen,Ronald G. Thomas,Scott M. Berry,Barbara A. Wendelberger,Scott W. Andersen,Karen C. Holdridge,Mark A. Mintun,Roy Yaari,John R. Sims,Monika Baudler,Paul Delmar,Rachelle S. Doody,Paulo Fontoura,Caroline Giacobino,Geoffrey A. Kerchner,Randall J. Bateman +64 more
TL;DR: A randomized, placebo-controlled, multi-arm trial of gantenerumab or solanezumab in participants with DIAD across asymptomatic and symptomatic disease stages was conducted in this paper.